SavedAdd your journal

Journals / Turkish Journal of Gastroenterology / 2014 / Cilt: 25 - Sayı: 6

Clostridium difficile infection and inflammatory bowel disease

Camelia COJOCARİU
Carol STANCİU
Oana STOİCA
Ana Maria SİNGEAP
Catalin SFARTİ
Irina GİRLEANU
Anca TRİFAN
Pages
603–610
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CDI may be difficult to distinguish from an IBD flare due to similar clinical presentation, and therefore screening for CDI is recommended at every flare in such patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Over the past 15 years, Clostridium difficile infection (CDI) in patients with inflammatory bowel disease (IBD) has increased both in incidence and severity.
📊
Key Findings & Data:Traditional risk factors for CDI are similar in IBD and non-IBD populations, but there is a significant proportion of IBD patients which have distinctive characteristics.
💡
Conclusion & Impact:CDI may be difficult to distinguish from an IBD flare due to similar clinical presentation, and therefore screening for CDI is recommended at every flare in such patients.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Over the past 15 years, Clostridium difficile infection (CDI) in patients with inflammatory bowel disease (IBD) has increased both in incidence and severity. Traditional risk factors for CDI are similar in IBD and non-IBD populations, but there is a significant proportion of IBD patients which have distinctive characteristics. Patients with ulcerative colitis (UC) are more susceptible to CDI and have more severe outcomes than those with Crohn's disease (CD). CDI may be difficult to distinguish from an IBD flare due to similar clinical presentation, and therefore screening for CDI is recommended at every flare in such patients. Several studies showed worse clinical outcomes in IBD patients with CDI, including longer hospital stay, higher colectomy and mortality rates than in those without CDI. Vancomycin and metronidazole appear to have similar efficacy in patients with moderate disease, but vancomycin is preferred in severe disease. Measures must be taken to prevent the spread of infection. Clinicians should have a high index of suspicion for CDI when evaluating a patient with IBD flare, as rapid detection and prompt treatment of infection improve outcomes. This review summarizes the available literature on epidemiology, risk factors, clinical aspects, diagnostic methods, treatment, outcome, and prevention of CDI in IBD patients.

🔖

Cite This Article

COJOCARİU, C., STANCİU, C., STOİCA, O., SİNGEAP, A. M., SFARTİ, C., GİRLEANU, I., TRİFAN, A. (2014). Clostridium difficile infection and inflammatory bowel disease. Turkish Journal of Gastroenterology, Cilt: 25 - Sayı: 6, 603–610. https://ajindex.com/articles/409456

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 2010; 4: 409-16
  2. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-87
  3. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008; 29: 823-8
  4. Marwick CA, Yu N, Lockhart MC, et al. Community-associated Clostridium difficile infection among older people in Tayside, Scotland, is associated with antibiotic exposure and care home residence: cohort study with nested case-control. J Antimicrob Chemother 2013; 68: 2927-33
  5. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365: 1693-1703
  6. Janarthanan S, Ditah I, Phil M, Adler GD, Ehrinpreis NM. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy. A Meta-analysis. Am J Gastroenterol 2012; 107: 1001-10
  7. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-41
  8. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-51
  9. Jen MH, Saxena S, Bottle A, Aylin P, Pollok RC. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 1322-31
  10. Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis 2009; 3: 4-7
  11. Ricciardi JO, Ogilvie W Jr., Roberts PL, Marcello PW, Concannon TW, Baxter NN. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel disease. Dis Col Rect 2009; 52; 40-5
  12. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-50
  13. LaMont JT, Trnka YM. Therapeutic implications on Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet 1980; 1: 381-3
  14. Navaneethan U, Venkatesh PGK, Shen B